Heart disease prevention may need fundamental recalibration as emerging evidence challenges the reliability of coronary calcium scoring—a widely used cardiovascular risk assessment tool—in patients with elevated lipoprotein(a). This finding could affect millions of adults who receive false reassurance from zero calcium scores despite harboring significant atherosclerotic risk.
Analysis of 11,319 participants across four major U.S. cohort studies revealed that individuals with lipoprotein(a) levels exceeding 50 mg/dL faced 28% higher cardiovascular event rates even when coronary calcium scores registered zero. Over nearly 15 years of follow-up, those with both elevated lipoprotein(a) and detectable calcium deposits experienced the highest risk—a three-fold increase in heart attacks, strokes, and coronary interventions compared to low-risk counterparts.
This discovery exposes a critical blind spot in contemporary cardiology practice. Coronary calcium scoring has become standard for intermediate-risk patients because calcium deposits typically correlate with atherosclerotic plaque burden. However, lipoprotein(a)—an inherited cholesterol variant affecting roughly 20% of the population—appears to promote noncalcified plaques that escape detection by calcium imaging. The research suggests that patients with elevated lipoprotein(a) require more aggressive preventive strategies regardless of calcium scores, potentially including earlier statin therapy, PCSK9 inhibitors, or emerging lipoprotein(a)-lowering treatments. While this single analysis requires validation in diverse populations, it represents a paradigm-shifting challenge to risk stratification algorithms that currently underestimate cardiovascular danger in a substantial subset of apparently low-risk individuals.